Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 22, 2026, 10:06 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Pediatric HIV Clear all
Active, not recruiting Phase 2Phase 3 Interventional

Study of Cobicistat-Boosted Atazanavir (ATV/co), Cobicistat-Boosted Darunavir (DRV/co) and Emtricitabine/Tenofovir Alafenamide (F/TAF) in Children With HIV

NCT02016924
View directory record Official record
Conditions
Acquired Immune Deficiency Syndrome (AIDS), HIV Infections
Interventions
ATV, DRV, Cobicistat, BR, F/TAF, LPV/r, Third Unboosted Drug, Cobicistat TOS, F/TAF TOS
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
4 Weeks to 17 Years
Enrollment
133 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2027
U.S. locations
7
States / cities
Long Beach, California • Los Angeles, California • Aurora, Colorado + 4 more
Source: ClinicalTrials.gov public record
Updated Apr 20, 2026 · Synced Sep 22, 2026, 10:06 PM EDT
Completed Phase 1 Interventional

Study to Assess the Acceptability of Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) Fixed-Dose Combination (FDC) Tablets in Human Immunodeficiency Virus Type 1 (HIV-1) Infected Pediatric Participants, Using Matching Placebo Tablets

NCT04006704
View directory record Official record
Conditions
HIV-1
Interventions
D/C/F/TAF FDC placebo
Drug
Lead sponsor
Janssen Pharmaceutica N.V., Belgium
Industry
Eligibility
6 Years to 11 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
4
States / cities
Phoenix, Arizona • Atlanta, Georgia • Memphis, Tennessee + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 5, 2021 · Synced Sep 22, 2026, 10:06 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Food-effect Study of the Pediatric Dispersible Tablet Formulations of TRIUMEQ® and DOVATO® in Healthy Adult Participants

NCT04827134
View directory record Official record
Conditions
HIV Infections
Interventions
TRIUMEQ, DOVATO
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years to 50 Years
Enrollment
33 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Jun 4, 2023 · Synced Sep 22, 2026, 10:06 PM EDT
Completed No phase listed Observational

Prevalence of Proteinuria and Chronic Kidney Disease in Pediatric HIV-Infected Patients

NCT00153621
View directory record Official record
Conditions
Chronic Kidney Failure, AIDS-Associated Nephropathy, HIV Infections
Interventions
Not listed
Lead sponsor
Children's National Research Institute
Other
Eligibility
1 Year to 21 Years
Enrollment
320 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated May 4, 2008 · Synced Sep 22, 2026, 10:06 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

A Phase II, Comparative Study of Seroconversion of Single-Dose and Two-Dose Measles Vaccination in HIV-Infected and HIV-Uninfected Children: A Multicenter Trial of the Pediatric AIDS Clinical Trials Group

NCT00000815
View directory record Official record
Conditions
HIV Infections, Measles
Interventions
Attenuvax, M-M-R-II
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
6 Months to 7 Months
Enrollment
270 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Ends 2001
U.S. locations
43
States / cities
Birmingham, Alabama • Long Beach, California • Los Angeles, California + 29 more
Source: ClinicalTrials.gov public record
Updated Oct 27, 2021 · Synced Sep 22, 2026, 10:06 PM EDT
Completed Phase 2 Interventional Results available

Doravirine/Islatravir (DOR/ISL) in Pediatric Participants With Human Immunodeficiency Virus Type 1 (HIV-1) Who Are <18 Years of Age and Weigh ≥35 kg (MK-8591A-028)

NCT04295772
View directory record Official record
Conditions
HIV-1 Infection
Interventions
DOR/ISL
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
Up to 17 Years
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
4
States / cities
Washington D.C., District of Columbia • Atlanta, Georgia • Baltimore, Maryland + 1 more
Source: ClinicalTrials.gov public record
Updated Jan 30, 2024 · Synced Sep 22, 2026, 10:06 PM EDT
Completed Phase 1 Interventional

A Study on the Management of Combination Anti-HIV Drug Therapy in HIV-Positive Children With Prior Treatment

NCT00000902
View directory record Official record
Conditions
HIV Infections
Interventions
Ritonavir, Nelfinavir mesylate, Nevirapine, Lamivudine, Stavudine, Zidovudine, Zalcitabine, Didanosine
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
6 Months to 21 Years
Enrollment
217 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2002
U.S. locations
59
States / cities
Birmingham, Alabama • Mobile, Alabama • La Jolla, California + 42 more
Source: ClinicalTrials.gov public record
Updated Oct 28, 2021 · Synced Sep 22, 2026, 10:06 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Transitioning HIV+ Adolescents to Adult Care: Exploring Adolescent and Adult Medicine Clinics Role in the Process

NCT02785302
View directory record Official record
Conditions
HIV
Interventions
Not listed
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 24 Years
Enrollment
136 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
14
States / cities
Los Angeles, California • Aurora, Colorado • Washington D.C., District of Columbia + 11 more
Source: ClinicalTrials.gov public record
Updated Feb 27, 2017 · Synced Sep 22, 2026, 10:06 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Bioavailability Study of a Dolutegravir Dispersible Tablet and Effect of Different Types of Water on the Dispersible Tablet in Healthy Volunteers

NCT02185300
View directory record Official record
Conditions
Infection, Human Immunodeficiency Virus
Interventions
Dolutegravir Pediatric Granules, Dolutegravir Dispersible Tablet
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years to 65 Years
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Dec 1, 2014 · Synced Sep 22, 2026, 10:06 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

To Assess the Relative Bioavailability (BA) of TRIUMEQ® and Dolutegravir and Lamivudine (DTG/3TC) Pediatric Dispersible Tablet Formulations in Healthy Volunteers

NCT03441984
View directory record Official record
Conditions
HIV Infections
Interventions
Treatment A, Treatment B, Treatment C, Treatment D, Treatment E, Treatment F
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years to 65 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Dec 8, 2019 · Synced Sep 22, 2026, 10:06 PM EDT
Completed No phase listed Observational

Correlation of HIV Levels With Clinical and Immunologic Outcome in Children Treated With Didanosine

NCT00026676
View directory record Official record
Conditions
HIV Infection
Interventions
Not listed
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Not listed
Enrollment
82 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2003
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2008 · Synced Sep 22, 2026, 10:06 PM EDT
Completed No phase listed Observational

The Use of a Distress Thermometer in a Pediatric Research Setting: An Exploratory Pilot Study

NCT00824278
View directory record Official record
Conditions
Cancer, HIV Infections
Interventions
Not listed
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
7 Years to 21 Years
Enrollment
289 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2018
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 16, 2019 · Synced Sep 22, 2026, 10:06 PM EDT
Terminated Phase 2Phase 3 Interventional Results available

Two Part Study to Evaluate Pharmacokinetics, Safety, and Antiviral Activity of Elvitegravir Administered With a PI/r Background Regimen for ARV Treatment-Experienced Pediatric Participants

NCT01923311
View directory record Official record
Conditions
Acquired Immune Deficiency Syndrome (AIDS), HIV Infections
Interventions
EVG, Background regimen
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
4 Weeks to 17 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
3
States / cities
Aurora, Colorado • Durham, North Carolina • Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Aug 8, 2018 · Synced Sep 22, 2026, 10:06 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess the Food Effect and the Relative Bioavailability of the Cabotegravir (CAB) Pediatric Dispersible Tablet (DT) Formulation

NCT05776108
View directory record Official record
Conditions
HIV Infections
Interventions
Cabotegravir IR Formulation (reference), Cabotegravir DT Formulation (test 1), Cabotegravir DT Formulation (test 2)
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years to 55 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Dec 12, 2023 · Synced Sep 22, 2026, 10:06 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

The Metabolic Effects of Protease Inhibitors in HIV Infected Children

NCT00004739
View directory record Official record
Conditions
HIV Infections
Interventions
Antiretroviral therapy
Drug
Lead sponsor
National Center for Research Resources (NCRR)
NIH
Eligibility
7 Years to 18 Years
Healthy volunteers
Accepts healthy volunteers
U.S. locations
2
States / cities
Houston, Texas • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Sep 22, 2026, 10:06 PM EDT
Completed Phase 4 Interventional Results available

Safety Sudy of Atazanavir Boosted With Ritonavir in the Treatment of HIV Infection in Pediatric Patients

NCT01691794
View directory record Official record
Conditions
HIV, Pediatric
Interventions
Atazanavir, Ritonavir
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
6 Years to 17 Years
Enrollment
108 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
3
States / cities
Phoenix, Arizona • Atlanta, Georgia • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Apr 26, 2018 · Synced Sep 22, 2026, 10:06 PM EDT
Completed Phase 1 Interventional Results available

Pharmacokinetics and Safety Study of Tipranavir in Combination With Low Dose Ritonavir in Human Immunodeficiency Virus (HIV)-Infected Children

NCT00076999
View directory record Official record
Conditions
HIV Infections
Interventions
TPV oral solution, RTV oral solution
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
2 Years to 18 Years
Enrollment
115 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2003
U.S. locations
9
States / cities
Los Angeles, California • Hartford, Connecticut • Chicago, Illinois + 5 more
Source: ClinicalTrials.gov public record
Updated May 11, 2014 · Synced Sep 22, 2026, 10:06 PM EDT
Completed No phase listed Observational

An Exploratory Study of the Use of Five Wishes as a Tool for Advanced Care Planning in Young Adults With Metastatic, Recurrent, or Progressive Cancer or HIV Infection

NCT01445145
View directory record Official record
Conditions
Neoplasms
Interventions
Not listed
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
16 Years to 30 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2014
U.S. locations
2
States / cities
Washington D.C., District of Columbia • Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 11, 2019 · Synced Sep 22, 2026, 10:06 PM EDT
Completed Phase 4 Interventional Results available

Equivalence of Boosted Atazanavir Based Regimens and Currently Effective HAART Regimens

NCT00940771
View directory record Official record
Conditions
Pediatric HIV, HIV Infections
Interventions
Boosted Atazanavir
Drug
Lead sponsor
Phoenix Children's Hospital
Other
Eligibility
6 Years to 18 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2016
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Apr 19, 2020 · Synced Sep 22, 2026, 10:06 PM EDT
Withdrawn Phase 3 Interventional

The Safety and Effectiveness of Methylprednisolone in the Treatment of Pneumocystis Carinii Pneumonia (PCP) in Children With AIDS

NCT00000741
View directory record Official record
Conditions
Pneumonia, Pneumocystis Carinii, HIV Infections
Interventions
Methylprednisolone
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
28 Days to 2 Years
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
6
States / cities
La Jolla, California • Chicago, Illinois • St Louis, Missouri + 2 more
Source: ClinicalTrials.gov public record
Updated Nov 3, 2021 · Synced Sep 22, 2026, 10:06 PM EDT
Completed Phase 3 Interventional

An Open-Label, Non-Randomized Trial to Evaluate the Tolerability and Safety of Viramune (Nevirapine) in Adult and Pediatric Patients With Progressive HIV Disease

NCT00002166
View directory record Official record
Conditions
HIV Infections
Interventions
Nevirapine
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
1 Day and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Ridgefield, Connecticut
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Sep 22, 2026, 10:06 PM EDT
Completed Phase 1 Interventional

The Safety and Effectiveness of Clarithromycin Plus Zidovudine or Dideoxyinosine in the Treatment of Mycobacterium Avium Complex (MAC) Infections in Children With AIDS

NCT00000971
View directory record Official record
Conditions
Mycobacterium Avium-intracellulare Infection, HIV Infections
Interventions
Clarithromycin, Zidovudine, Didanosine
Drug
Lead sponsor
Abbott
Industry
Eligibility
3 Months to 18 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
2
States / cities
Los Angeles, California • Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 3, 2008 · Synced Sep 22, 2026, 10:06 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Long-Term Effects of HIV Exposure and Infection in Children

NCT00006304
View directory record Official record
Conditions
HIV Infections, HIV Seronegativity
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
24 Hours to 21 Years
Enrollment
4,150 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Ends 2002
U.S. locations
89
States / cities
Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 52 more
Source: ClinicalTrials.gov public record
Updated Oct 6, 2013 · Synced Sep 22, 2026, 10:06 PM EDT
Completed Not applicable Interventional

Pneumococcal Vaccine and Routine Pediatric Immunizations in HIV-Infected Children Receiving Anti-HIV Drugs

NCT00013871
View directory record Official record
Conditions
HIV Infections, Hepatitis B, Measles, Pneumococcal Infections, Pertussis
Interventions
Diphtheria & Tetanus Toxoids & Acellular Pertussis Vaccine Adsorbed, Measles-Mumps-Rubella Vaccine (Live), Pneumococcal Vaccine, Polyvalent (23-valent), Pneumococcal Conjugate Vaccine, Heptavalent, Hepatitis B Vaccine (Recombinant)
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
2 Years to 18 Years
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2004
U.S. locations
38
States / cities
Birmingham, Alabama • Long Beach, California • Los Angeles, California + 26 more
Source: ClinicalTrials.gov public record
Updated Oct 31, 2021 · Synced Sep 22, 2026, 10:06 PM EDT